- Home
- VECO vs NVCR Comparison
VECO vs NVCR Comparison
Compare VECO & NVCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VECO
- NVCR
- Stock Information
- Founded
- VECO 1945
- NVCR 2000
- Country
- VECO United States
- NVCR Jersey
- Employees
- VECO N/A
- NVCR N/A
- Industry
- VECO Industrial Machinery/Components
- NVCR Medical/Dental Instruments
- Sector
- VECO Technology
- NVCR Health Care
- Exchange
- VECO Nasdaq
- NVCR Nasdaq
- Market Cap
- VECO 1.9B
- NVCR 3.2B
- IPO Year
- VECO 1994
- NVCR 2015
- Fundamental
- Price
- VECO $27.00
- NVCR $29.99
- Analyst Decision
- VECO Buy
- NVCR Buy
- Analyst Count
- VECO 7
- NVCR 5
- Target Price
- VECO $42.14
- NVCR $33.40
- AVG Volume (30 Days)
- VECO 543.3K
- NVCR 1.1M
- Earning Date
- VECO 02-12-2025
- NVCR 02-20-2025
- Dividend Yield
- VECO N/A
- NVCR N/A
- EPS Growth
- VECO N/A
- NVCR N/A
- EPS
- VECO 1.35
- NVCR N/A
- Revenue
- VECO $709,094,000.00
- NVCR $577,738,000.00
- Revenue This Year
- VECO $8.83
- NVCR $19.13
- Revenue Next Year
- VECO $2.69
- NVCR $5.38
- P/E Ratio
- VECO $19.93
- NVCR N/A
- Revenue Growth
- VECO 9.71
- NVCR 14.63
- 52 Week Low
- VECO $25.52
- NVCR $11.70
- 52 Week High
- VECO $49.25
- NVCR $34.13
- Technical
- Relative Strength Index (RSI)
- VECO 42.66
- NVCR 58.14
- Support Level
- VECO $26.62
- NVCR $29.62
- Resistance Level
- VECO $28.09
- NVCR $32.06
- Average True Range (ATR)
- VECO 0.93
- NVCR 1.80
- MACD
- VECO -0.05
- NVCR -0.60
- Stochastic Oscillator
- VECO 10.27
- NVCR 8.20
About VECO Veeco Instruments Inc.
Veeco Instruments Inc is a United States-based company that is principally engaged in designing, developing, and manufacturing thin-film process equipment, which is mainly used to produce electronic devices. The company's product categories by market consist of lighting, display, and power electronics; advanced packaging; MEMS and RF; scientific and industrial; and data storage. The lighting, display, and power electronics market accounts for over half of the total revenue. The company offers products and services in the United States; China; Europe, the Middle East, and Africa, or EMEA; and the rest of the world, with overseas markets contributing the majority of total revenue.
About NVCR NovoCure Limited
NovoCure Ltd serves in the healthcare sector of the United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.